Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2029-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare how well tolerated and effective four different
dosing schedules (two personalized, intermittent dosing schedules as compared to a fixed
intermittent and continuous dosing regimen) work in people with advanced basal cell
carcinoma.
Phase:
Early Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute